其中843例(0.7%)检出PD-L1扩增(拷贝数≥6个),而肺腺癌、肺鳞癌、小细胞肺癌中PD-L1(CD274)扩增发生率分别为0.6%、1.7%、1.3%,至于PD-L1(CD274)扩增是否能够预测免疫治疗疗效,目前还很难定论,需要前瞻性研究进一步确认其预测价值[2]。
[1]Iván Pérez-Núñez et al. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature Cancer(2022). [2]An mRNA therapy improves breast cancer response to immunotherapy in mice(来源:FierceBiotech) [3]Radical ...
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC—The Phase 2 CONDOR Randomized Clinical Trial Durvalumab联合/不联合Tremelimumab在PD-L1水平低或阴性...
[1]Iván Pérez-Núñez et al. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature Cancer(2022). [2]An mRNA therapy improves breast cancer response to immunotherapy in mice(来源:FierceBiotech) ...
PD-1/PD-L1免疫治疗药物可通过激活人体的免疫系统达到攻击肿瘤细胞的效果,而肠道菌群的平衡对人体的免疫系统起着至关重要的作用。广谱抗生素的使用,会导致肠道菌群失调,进而导致肿瘤患者体内的免疫反应紊乱,最终大幅度降低PD-1/PD-L1免疫治疗药物的疗效。
正常生理状况下，PD-1/PD-L1抑制性共刺激信号的主要作用是防止T细胞不受控制地过度活化攻击正常细胞。不同类型肿瘤细胞表面表达高水平的PD-L1，这些过度表达的PD-L1通过PD-1/PD-L1信号途径诱导T细胞衰竭，使肿瘤细胞逃避T细胞免疫攻击，直接影响肿瘤患者的治疗效果及临床预后。PD-1/PD-L1通路阻断剂，包括PD-1单...
简评：PD-1算是肿瘤治疗百年难遇的神药，后PD-1时代，基于PD-1/PD-L1的联合治疗是药物开发及临床使用的重点。但联合治疗的一个主要问题：毒性...主要参考文献 Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379: ...
程序性细胞死亡蛋白1(programmed cell death protein 1,PD-1)/程序性死亡配体1(programmed death-ligand 1,PD-L1)是导致肿瘤免疫逃逸的重要免疫检查点分子,阻断PD-1/PD-L1可以重新激活细胞毒性T细胞对肿瘤的杀伤作用,是一种重要的肿瘤免疫治疗方式。肿瘤细胞中PD-L1的表达可能影响抗PD-1/PD-L1治疗的临床疗效。
放射组学和EV PD-L1动力学的结合是一种微创且有前景的生物标志物,可用于对接受ICIs的患者进行分层。(Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC. J Exp Clin Cancer Res. 2024;43(1):81. IF=11.4 1区)...
[3]Wu Y, Chen W, Xu Z P, et al. PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition[J]. Frontiers in immunology, 2019,10:2022. [4]Nowicki T S, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade[J]. Cancer J...